Cargando…
Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE)
BACKGROUND: Treatment for ovarian cancer includes platinum-based chemotherapy, but many women become resistant to chemotherapy, becoming platinum-resistant. Standard of care for these women is weekly paclitaxel chemotherapy, but cancers can often become paclitaxel resistant. TAK228, an investigation...
Autores principales: | de la Rosa, Consuelo Nóhpal, Krell, Jonathan, Day, Emily, Clarke, Aaron, Reddi, Meena, Webber, Lee, Fiorentino, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728702/ https://www.ncbi.nlm.nih.gov/pubmed/34986897 http://dx.doi.org/10.1186/s13063-021-05669-9 |
Ejemplares similares
-
DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment—a study protocol for a randomised trial investigating a novel therapy called TAK228
por: Fiorentino, Francesca, et al.
Publicado: (2022) -
Facial pyoderma gangrenosum associated with fallopian tube carcinosarcoma
por: Mardani, Ghazal, et al.
Publicado: (2023) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel
por: Kobayashi, Yusuke, et al.
Publicado: (2021) -
A Case of Endometrial Carcinosarcoma Containing Sertoliform Endometrioid Carcinoma Component
por: Munakata, Satoru, et al.
Publicado: (2021)